Myeloma

December 22, 2021

ECOG-ACRIN Research at ASH 2021

Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
August 17, 2021

Now Enrolling: EAA171/OPTIMUM for Myeloma

This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
February 25, 2021

Trial Spotlight: Shaji Kumar on the EQUATE Study for Newly Diagnosed Multiple Myeloma

The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
December 14, 2020

Now Enrolling: ECOG-ACRIN Opened Five New Trials in October

The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
December 14, 2020

ECOG-ACRIN Names University of Pennsylvania’s Bonnie Ky As Its Young Investigator of the Year

Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction
June 10, 2020

From the Co-Chairs, June 2020

Strong EA research presence at ASCO 2020; the horrific killing of George Floyd; health equity and diversity in the field of oncology; the need for EA to participate in changing a specifically anti-racist culture and increase diversity and inclusion